Introduction
============

The essence of the mitochondria lies within their ability to generate energy, maintain metabolisms, and regulate signaling cascades. As fundamental constituents of numerous rudimentary cellular processes, the molecular architecture and the proteome of the mitochondria are critical to intracellular biochemistry. The behavior of the mitochondria is subjugated to the environment of this organelle; perturbation of mitochondrial homeostasis can prompt pathophysiological conditions to arise.

The history of mitochondrial research can be traced back to Rudolf Albrecht von Kolliker in 1857 when he first described the mitochondrion. In 1890, Richard Altmann termed the mitochondria "bioblasts," noted their ubiquitous nature, and showed exceptional foresight when he explained that these bioblasts were living inside cells and were responsible for "elementary functions." The endosymbiotic theory was first articulated by Konstantin Mereschkowski in 1905. Although several hypotheses were put forth to explain the merger between mitochondria and cells, it was Lynn Margulis who tied the endosymbiotic theory to biochemical and cytological evidence. Mitochondria are of α-protobacterial origin, engulfed by cells through endosymbiosis about two billion years ago. The name "mitochondrion" was first introduced in 1898 by Carl Benda from the Greek words "mitos" (thread) and "chondros" (granule). The first well-preserved mitochondria were isolated by [@bib23]. This approach proved to be significantly advantageous to mitochondrial research for several decades, in particular, on the characterization of mitochondrial proteome biology and function which we focus today. A key result from the remarkable hypothesis of chemiosmosis by Mitchell ([@bib17]) is an organized subproteome, i.e., the electron transport complexes, with a dedicated role, supporting the oxidation and phosphorylation function in the mitochondria. The significance of the respiratory complexes to biology has been highly recognized, but that to the proteome design was much less appreciated. The complexity of this apparatus was further realized with the introduction of innovative methods to visualize three-dimensional structures and the role of the mitochondria in cell death signaling ([@bib17]). These findings inspired the research efforts to link biological pathways with their subproteome-based molecular participants in the regulation of mitochondrial function. [Fig. 1](#fig1){ref-type="fig"} summarizes the milestones of the long and fruitful history of mitochondrial research.

![Milestones in mitochondrial research. Representative milestones in mitochondrial research, including mitochondrial function, structure, and mitochondrial medicine, are listed in a chronological sequence (1890--current). Our apologies to those not represented in this timeline.](JGP_201210797R_Fig1){#fig1}

The relationship between mitochondria and disease has been firmly established, with one of the first reported mitochondrial diseases by Rolf Luft and colleagues at Karolinska University in Stockholm, Sweden. A patient was presented with hypermetabolism unrelated to thyroid dysfunction. Through morphological (increased number of mitochondria) and biochemical (loosely coupled mitochondrial oxidative phosphorylation \[OXPHOS\]) evidence, this group of investigators concluded that mitochondria were the source of these symptoms, marking the beginning of an era of mitochondrial medicine. Throughout the 1970s, other landmark discoveries singled out specific metabolic as well as enzymatic deficiencies, such as pyruvate dehydrogenase and carnitine palmitoyltransferase deficiencies. Over 20 years passed between the discovery of mitochondrial DNA (mtDNA) and its mapping. In 1988, for the first time, mutations in mtDNA-associated diseases were reported ([@bib56]). As the detection of mitochondrial dysfunctions became more prevalent, the identification of mitochondrial components, as well as the characterization of mitochondrial proteome dynamics, increased in relevance. This Perspective will provide current knowledge of mitochondrial biology and an update on the design of the mitochondrial proteome, with an effort to contextualize mitochondrial proteomes to their biological pathways and the consequences of the proteome compositions to clinical phenotypes.

Proteins supporting mitochondrial structure and biology
=======================================================

The mitochondrion is an organelle comprised of four distinct compartments---the outer mitochondrial membrane (OMM), the intermembrane space, the inner mitochondrial membrane (IMM), and the matrix---which are bordered by its unique double-membrane structure. Production and transportation of electrolytes are facilitated by proteins embedded within the membranes. Approximately 1,000 proteins have been identified by several proteomic investigations ([@bib41]; [@bib54]; [@bib18]; [@bib30]; [@bib43]; [@bib61]) to support mitochondrial structure and function. [Fig. 2](#fig2){ref-type="fig"} summarizes the major mitochondrial cellular processes, their subproteomes, and their involvements in metabolic diseases.

![Schematic overview of mitochondrial subproteomes in health and disease. This figure contextualizes mitochondrial proteomes to their biological pathways and the consequences of the proteome compositions to clinical phenotypes. Mitochondrial pathways responsible for fundamental cellular functions within the cell, including OXPHOS, TCA cycle, β oxidation, apoptosis, proteolysis, redox, protein import, and calcium regulation, are detailed. Other mitochondrial functions related to specific cell types are not listed. Within each mitochondrial subproteome, the first number represents the total number of proteins associated with its function (the number of proteins was collected in our previous study; [@bib61]); the next number inside the parentheses (\*) signifies the portion of the total proteins in this particular subproteome reported to be implicated in metabolic diseases.](JGP_201210797R_Fig2){#fig2}

The majority of proteins comprising the mitochondria are encoded by nuclear DNA. However, unlike their surrounding organelles, mitochondria possess their own DNA, which acts as scripts for the 13 proteins constituting seven proteins for complex I, one for complex III, three for complex IV, and two for complex V of the electron transport chain (ETC), also known as the respiratory complexes. In most multicellular organisms, mtDNA are inherited maternally. Because there are many copies of mtDNA and there are many mitochondria in all cell types, most mitochondrial mutations often have few detrimental effects on mitochondrial function until they reach sufficient number, a "threshold effect." Not surprisingly, this threshold effect is lower in highly aerobic tissues such as the eye, brain, and heart ([@bib14]). Therefore, under pathogenic mitochondrial conditions, these tissues are vulnerable and may be affected, indicative of mitochondrial dysfunction. To date, proteomic approaches have been successful in characterizing the subproteome supporting OXPHOS function, including the identification of 88 proteins from the human heart ([@bib54]) and 96 proteins from the mouse heart ([@bib61]). These proteins represent 90% or more of the entire OXPHOS subproteome (nuclear and mDNA combined). The remaining 10% of the OXPHOS proteins are known only by their genetic information, but are undetected by proteomic methods. They may have exceptionally low abundance or may carry unique biochemical properties (e.g., hydrophobic proteins); their protein characterization may require approaches with higher sensitivity (e.g., antibodies).

As the key energy producer of the cell, the mitochondrion is fundamental for many metabolic processes. The products of glycolysis enter the mitochondrial matrix to continue their conversion to energy in the tricarboxylic acid (TCA) cycle, which possesses a subproteome composed of 11 proteins in the mouse cardiac mitochondria ([@bib61]). Subsequently, NADH and FADH~2~ proceed to donate electrons to the ETC components, eventually reducing oxygen to water. An electrochemical gradient is established and maintained to harness the energy produced by the subsequent flow of protons back into the matrix to synthesize ATP from ADP and phosphate.

Calcium plays a multifaceted role in mitochondrial function. Mitochondrial calcium regulation can be denoted by influx, matrix buffering, and efflux ([@bib58]; [@bib20]). A total of 61 proteins from the mouse heart ([@bib61]) has been reported to support calcium regulation in mitochondria. Mitochondria have been implicated as fundamental in the induction of cell death; two differential processes have been shown to lyse the cells: necrosis and apoptosis. The protein identities defining both the necrosis and apoptosis pathways are only partially understood. Release of apoptotic factors such as cytochrome c, Smac/Diablo, and apoptosis-induced factors into the cytosol attracts caspase-9 and apoptotic protease-activating factor 1 to form the apoptosome with ATP. The Bcl-2 family proteins are also activated during the apoptotic process. A total of 26 proteins in the mouse heart ([@bib61]) has been identified to be related to apoptosis. In parallel, mitochondria produce free radicals by leaking electrons to oxygen in the process of transferring electrons through the ETC, in particular complexes I and III. To counteract this, endogenous scavenging enzymes and antioxidants are activated to eliminate reactive oxygen species (ROS); this defense system includes superoxide dismutases, catalase, peroxidredoxin, glutathione peroxidase, and reduced glutathione. Currently, 29 proteins in the human heart are affiliated with redox functions ([@bib54]), whereas 32 proteins were reported in the mouse heart. However, when the system is challenged to rapidly convert ROS to water, oxidative damage will accumulate, leading to mitochondrial dysfunction.

Mitochondrial proteases participate not only in protein proteolysis ([@bib33]), but they also are emerging as crucial regulators of mitochondrial function. The many types of mitochondrial proteases include the PIM1/Lon protease, the mitochondrial intermembrane space protease I and the ClpXP protease in the matrix, and the i-AAA protease and the m-AAA protease residing in the IMM. Proteases are shown to play essential roles in mitochondrial morphology maintenance, mitochondrial biogenesis, and mitochondrial metabolism regulation ([@bib5]). Mitochondrial proteases are evolutionarily conserved from yeast to humans in support of the evolutionary prokaryotic ancestors. Disturbances of the mitochondrial proteolytic system affect mitochondrial homeostasis. Thus far, 40 proteases were reported from the mouse heart ([@bib61]) in the mitochondria.

Proteome profiling of mitochondria
==================================

The mitochondrial proteome is unique, complex, and dynamically regulated as it adapts to the needs of the tissues or disease states ([@bib27]; [@bib2]). Over the past decade, tremendous efforts have been made to explore mitochondrial subproteomes and their posttranslational modifications (PTMs) in both physiological and pathological environments. Indeed, mitochondrial proteomes in various organisms and tissues, including yeast ([@bib50]), mouse ([@bib41]; [@bib30]; [@bib43]; [@bib61]), human ([@bib54]; [@bib19]), rat ([@bib18]; [@bib47]; [@bib27]), and drosophila ([@bib1]) have been investigated. [Fig. 3](#fig3){ref-type="fig"} deciphers the state-of-the-art experimental workflow used in mitochondrial proteomic studies, including mitochondrial isolation, purification, mass spectrometry (MS) identification, and data analyses.

![Current state-of-the-art technology platform to characterize mitochondrial proteomes. This figure depicts the current technology platform used to characterize mitochondrial proteomes from model systems, including mitochondrial preparation, protein/peptide fractionations, MS instrumentation, protein identification/PTM analyses, protein quantification, and data validation.](JGP_201210797R_Fig3){#fig3}

Preparation of pure and functionally viable mitochondria is an important first step to achieving reliable and reproducible proteomic outputs. [@bib23] developed the first protocol to isolate rat liver mitochondria based on a differential centrifugation. Thereafter, isolation methods have been modified and tailored based on different tissues and species. Mitochondria could be further purified by free-flow electrophoresis or density gradient centrifugation with either percoll or other dense materials such as metrizamide, sucrose, and nycodenz. Mitochondrial purity and intactness could be validated by immunoblottings using specific organelle protein markers, membrane potential measurements, and respiratory control index assessments, as well as electron microscopy morphology detection ([@bib61]). If a particular mitochondrial subproteome, such as OMM, IMM, or OXPHOS, is the subject of interest, isolation of these subcompartments is desirable. Sample fractionation has been frequently applied to reduce the complexity before the sample is subjected to MS analyses. Different approaches have been used, including gel-based approaches such as one-dimensional SDS-PAGE, two-dimensional PAGE (2-DE), and blue native PAGE, as well as gel-free--based approaches such as immunoprecipitation, liquid chromatography (LC), and free-flow electrophoresis. Different separation approaches are complementary. 2-DE is preferred to separate soluble and high-abundance proteins but poorly resolves hydrophobic proteins, low-abundance proteins, and proteins with extreme isoelectric point values. The combination of a blue native PAGE and a SDS-PAGE could be used to enrich the identification of OXPHOS protein complexes ([@bib47]). Gel-free--based shotgun proteomic analyses, combining a strong cation exchange LC and a reversed-phased LC, are beneficial for the detection of proteins with low abundance and high hydrophobicity.

An early study on mitochondrial proteomes by [@bib45] was conducted on human placental mitochondria using 2-DE followed by MS analyses; they reported a total of 46 proteins. Subsequently, Taylor and his collaborators ([@bib54]; [@bib19]) characterized the human cardiac mitochondrial proteome using SDS-PAGE separation and multidimensional LC coupled with MS analyses, where 722 proteins were reported. Furthermore, [@bib41] characterized mitochondrial proteomes from the mouse brain, heart, liver, and kidney samples. 399 proteins were identified from proteomic studies and 428 proteins were reported from gene annotation analyses, combining for a total of 591 distinct proteins from different tissues. Among these 399 proteins, 107 proteins were conserved across tissues. Later, [@bib30] performed a global proteomic survey of four organellar compartments (cytosol, membranes, mitochondria, and nuclei) in six mouse organs. 4,768 proteins were identified, of which 1,075 proteins were localized in the brain mitochondria, 667 in the heart mitochondria, 789 in the kidney mitochondria, 775 in the liver mitochondria, 1,072 in the lung mitochondria, and 901 in the placenta mitochondria. Among these mitochondrial proteins, only 132 proteins were conserved across tissues. Later on, studies by [@bib61] identified 940 distinct proteins from mouse cardiac mitochondria using functionally validated mitochondria, among which 480 proteins were not identified by the aforementioned major proteomic profiling studies ([@bib41]; [@bib54]; [@bib30]). Additionally, [@bib43] combined MS analyses with GFP tagging, as well as machine learning, and created a mitochondrial compendium of 1,098 genes and their protein expressions across 14 different mouse tissues. By linking the characterized proteins in this inventory to known mitochondrial pathways, 19 proteins were predicted to be important for the function of ETC complex I, of which one protein (C8orf38) was further validated. Many methodological issues may contribute to these mitochondrial proteome differences as reported by their MS-based identifications. There are issues using mitochondrial samples from different tissues, including sample preparations, contaminants from abundant proteins, the overall molecular compositions of the targeted mitochondrial proteome, the dynamic ranges of protein abundance in the particular mitochondrial proteome of interest, etc. Apart from these technical factors, it is highly possible that the reported diversity in mitochondrial proteomes is a result of their tissue specificity. Despite the variability of MS-based proteomic approaches, the proteomic results from different research groups indicate the heterogeneity of mitochondrial proteomes among the rat/mouse tissues ([@bib18]; [@bib30]; [@bib26],[@bib27]). These inter-tissue comparisons recognize that the mitochondrial proteomes are tuned to meet the metabolic and signaling requirements of their environment. For example, heart mitochondria require a constant and stable supply of ATP to maintain cardiac function, whereas the liver mitochondria are orientated toward a more biosynthetic role conducive for metabolic function. In addition, using a combination of comparative genomics and computational algorithms, the interspecies comparisons support the notion of the existence of conserved and heterogeneous proteins in the mitochondrial proteome ([@bib48]).

The four subcompartments of the mitochondria are comprised of different protein contents. The matrix incorporates approximately two thirds of the mitochondrial proteins, with the IMM containing 21%, the intermembrane space occupying ∼6%, and the OMM encompassing a mere 4% of the overall proteins of the mitochondrion ([@bib15]). These values are still under investigation as low-abundance proteins are difficult to detect with the current technology. Using organic acid, [@bib10] extracted the IMM fractions of hepatocytes and found 182 proteins using a 2-DE-LC-MS/MS. [@bib39] further identified 348 proteins through three separation techniques (2D-LC with ProteomeLab PF 2D Protein Fractionation System, 2-DE, and RP-HPLC). A two-step digestion with trypsin and proteinase K facilitated the detection of OMM proteins previously unidentified ([@bib15]). Another study of *Saccharomyces cerevisiae* by [@bib60] encountered 112 OMM proteins, including integral and peripheral membrane proteins.

In parallel to protein identification, two main strategies have been applied to the quantitative mitochondrial proteomic analyses: an MS-based label-free approach and differential labeling quantitative techniques. The label-free quantification is based on either the measurement of the peptide precursor intensity ions of a protein or the number of fragmented spectra peptides of a protein. This approach has been successfully used in the comparison of mitochondrial proteome changes under physiological and pathological conditions in various animal models ([@bib18]; [@bib26]). Isotope-labeling experiments include two-dimensional difference in-gel electrophoresis (2D-DIGE), isotope-coded affinity tag, isobaric tags for relative and absolute quantitation (iTRAQ), and stable isotopic labeling by amino acids in cell culture (SILAC), as well as stable isotopic labeling in mammals (SILAM). These approaches are more accurate, but the reagents are costly and require specialized bioinformatics tools.

In recent years, several databases of mitochondrial proteins have been created, including MitoP2 ([@bib16]), Mitoproteome ([@bib9]), MitoCarta ([@bib43]), MitoMiner ([@bib51]), as well as COPaKB, i.e., the Cardiac Organellar Protein Atlas Knowledgebase (<http://www.heartproteome.org>). These databases list mitochondrial proteins identified via multiple approaches, including MS/MS analyses, literature curations, and bioinformatics evaluations. COPaKB is an integrated resource of proteome biology configured to specifically focus on cardiovascular biology and medicine. Its first release includes proteomic data from large-scale proteomic surveys of cardiac mitochondrial proteins.

Defining the mitochondrial proteome is a challenge because of the dynamics of this organelle. Approximately 293 out of 940 proteins identified were found to contain mitochondrial targeting sequences ([@bib61]). In contrast, a majority of proteins do not bear the mitochondrial targeting sequences; however, they can travel to multiple subcellular localizations in parallel to their mitochondrial residency. Some proteins anchor onto the outer membrane of mitochondria with a loose attachment; they are called mitochondrial-associated proteins. Targeting sequence prediction cannot be used as a sole strategy to validate the mitochondrial localization of proteins caused by a higher false-positive prediction rate as well as multiple protein import mechanisms. Some mitochondrial proteins are only expressed in certain developmental stages or specific species. Furthermore, some mitochondrial proteins are expressed in very low abundances and do not meet the detection threshold criteria of MS. Collectively, the above issues (the nature of mitochondrial proteins and the technological limitations) contribute to the current discrepancy of the existing mitochondrial proteome datasets.

PTM of mitochondrial proteins
=============================

Major protein PTMs including phosphorylation, acetylation, S-nitrosylation (SNO), succinylation, and O-GlcNAcylation are reported to take place in the mitochondrial proteome ([@bib13]; [@bib22]; [@bib59]; [@bib62]). Together, these PTMs orchestrate the functions of mitochondrial proteins by modulating their subcellular localizations, protein--protein interactions, and stability. For example, phosphorylation has been shown to regulate essential metabolic flux into the TCA cycle ([@bib4]) and the assembly of the ETC complexes ([@bib28]; [@bib44]).

Understanding the molecular and physiological roles of PTMs in mitochondria is a pivotal step toward advancing our knowledge in mitochondrial biology. As in proteome profiling, the literature reflects the indispensability of MS technology in PTM analyses. Numerous mitochondrial PTMs have now been unequivocally discerned by MS-based proteomics experiments ([@bib4]). [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"} list representative human and mouse cardiac mitochondrial proteins from the TCA cycle and ETC complexes, and their respective phosphorylation and acetylation sites identified through large-scale MS screening, as indicated in UniProt (The [@bib55]). The functions and regulations of these PTMs are currently under intense investigations.

###### 

Known phosphorylation sites on UniProt among ETC and TCA proteins in the mouse and human heart

  Protein name                                    Species   UniProt accession   Phosphorylation site(s)
  ----------------------------------------------- --------- ------------------- -------------------------
  ATP synthase subunit e                          Mouse     Q06185              Y32
  ATP synthase subunit γ                          Mouse     Q91VR2              S146
  ATP synthase subunit α                          Mouse     Q03265              S76
  ATP synthase subunit β                          Mouse     P56480              S529
  Cytochrome b-c1 complex subunit 1               Human     P31930              T381
  Cytochrome b-c1 complex subunit 2               Human     P22695              T86
  Cytochrome b-c1 complex subunit 6               Human     P07919              S61
  Cytochrome b-c1 complex subunit 6               Mouse     P99028              T61
  Fumarate hydratase                              Human     P07954              Y491
  Isocitrate dehydrogenase subunit γ              Mouse     P70404              T363
  Malate dehydrogenase                            Human     P40926              Y56
  NADH-ubiquinone oxidoreductase 18-kD subunit    Human     O43181              T32, S34
  NADH-ubiquinone oxidoreductase B22 subunit      Human     Q9Y6M9              S85
  NADH-ubiquinone oxidoreductase PDSW subunit     Human     O96000              Y56, Y143
  NADH-ubiquinone oxidoreductase subunit 2        Human     P03891              T258
  NADH-ubiquinone oxidoreductase subunit B14.5a   Human     O95182              S63
  Succinate dehydrogenase flavoprotein subunit    Mouse     Q8K2B3              T252
  Succinyl-CoA synthetase β-A chain               Mouse     Q9Z2I9              S279
  Succinyl-CoA synthetase β-A chain               Human     Q9P2R7              Y84

Proteins from ETC complexes and the TCA cycle were experimentally determined from mouse and human heart mitochondria. The PTM information of the protein was retrieved from UniProt. The referenced phosphorylation sites were identified from their respective species but may have originated from different tissues other than the heart (e.g. mouse liver, human HeLa cells). Tissue-specific PTM distribution is a matter of intense investigation.

###### 

Known acetylation sites on UniProt among ETC and TCA proteins in the mouse and human heart

  Protein name                                     Species   UniProt accession   Acetylation site(s)
  ------------------------------------------------ --------- ------------------- ------------------------------------------------------
  Aconitase                                        Human     Q99798              K50, K573, K605
                                                   Mouse     Q99KI0              K50
  Acyl carrier protein                             Human     O14561              K92
  ATP synthase protein 8                           Mouse     P03930              K54
  ATP synthase subunit b                           Human     P24539              K221, K233
                                                   Mouse     Q9CQQ7              K115, K131, K162, K188, K221, K225, K233
  ATP synthase subunit d                           Human     O75947              K85, K95, K117, K149
                                                   Mouse     Q9DCX2              K63, K78, K85, K99, K117, K149
  ATP synthase subunit f                           Human     P56134              A2
  ATP synthase subunit g                           Human     O75964              A2, K24
                                                   Mouse     Q9CPQ8              K54, K66
  ATP synthase subunit γ                           Human     P36542              K55, K154, K197
                                                   Mouse     Q91VR2              K79, K90, K115
  ATP synthase subunit O                           Human     P48047              K54, K60, K70, K162, K172, K192
                                                   Mouse     Q9DB20              K60, K70, K158, K162, K172, K176, K192
  ATP synthase subunit α                           Human     P25705              K161, K261, K305, K434, K498, K506, K539
                                                   Mouse     Q03265              K132, K230, K239, K261, K305, K427, K498, K531, K539
  ATP synthase subunit β                           Human     P06576              K133, K198, K426, K485
                                                   Mouse     P56480              K133, K259, K522
  ATP synthase-coupling factor 6                   Human     P18859              K41, K46, K99, K105
                                                   Mouse     P97450              K84, K99
  Citrate synthase                                 Human     O75390              K327, K366, K375, K382, K393
  Cytochrome b-c1 complex subunit 1                Human     P31930              K111
  Cytochrome b-c1 complex subunit 2                Mouse     Q9DB77              K159, K250
  Cytochrome b-c1 complex subunit 6                Human     P07919              K85
                                                   Mouse     P99028              K40
  Cytochrome b-c1 complex subunit 7                Human     P14927              K78
  Cytochrome c oxidase polypeptide VIc             Mouse     Q9CPQ1              K61
  Cytochrome c oxidase subunit 4 isoform 1         Human     P13073              K53, K60
  Cytochrome c oxidase subunit 5B                  Human     P10606              K121
  Cytochrome c oxidase subunit 7A-related          Human     O14548              K69
  Dihydrolipoyl dehydrogenase                      Human     P09622              K143, K267, K320, K410, K417, K420
                                                   Mouse     O08749              K127
  Fumarate hydratase                               Human     P07954              K66, K80, K94, K256, K292
                                                   Mouse     P97807              K63, K112, K474
  Isocitrate dehydrogenase subunit β               Human     O43837              K146, K199, K374
  Isocitric dehydrogenase subunit α                Human     P50213              K343
  Malate dehydrogenase                             Human     P40926              K165, K185, K301, K307, K314, K329, K335
                                                   Mouse     P08249              K157, K239, K314
  NADH-ubiquinone oxidoreductase 13-kD A subunit   Mouse     P52503              K112
  NADH-ubiquinone oxidoreductase 13-kD B subunit   Mouse     Q9CPP6              K36, K46, K98
  NADH-ubiquinone oxidoreductase 39-kD subunit     Mouse     Q9DC69              K370
  NADH-ubiquinone oxidoreductase 42-kD subunit     Mouse     Q99LC3              K122, K181, K242, K350
  NADH-ubiquinone oxidoreductase 51-kD subunit     Mouse     Q91YT0              K81, K104, K375
  NADH-ubiquinone oxidoreductase 75-kD subunit     Mouse     Q91VD9              K84
  NADH-ubiquinone oxidoreductase B12 subunit       Mouse     Q9CQZ6              K29, K40
  NADH-ubiquinone oxidoreductase B22 subunit       Human     Q9Y6M9              A2
  NADH-ubiquinone oxidoreductase B8 subunit        Human     O43678              A2
                                                   Mouse     Q9CQ75              K64, K75
  NADH-ubiquinone oxidoreductase MLRQ subunit      Mouse     Q62425              K56
  NADH-ubiquinone oxidoreductase subunit B14.5b    Human     O95298              K114
  NADH-ubiquinone oxidoreductase subunit B17.2     Mouse     Q7TMF3              K43, K47
  Succinate dehydrogenase flavoprotein subunit     Human     P31040              K179, K335, K541, K547, K608
                                                   Mouse     Q8K2B3              K179, K423, K485, K498, K538, K547
  Succinyl-CoA synthetase β A chain                Human     Q9P2R7              K78, K143
  Succinyl-CoA synthetase β G chain                Human     Q96I99              K73, K227, K291, K338
  Succinyl-CoA synthetase subunit α                Human     P53597              K54

Proteins from ETC complexes and the TCA cycle were experimentally determined from mouse and human heart mitochondria. The PTM information of the protein was retrieved from UniProt. The referenced acetylation sites were identified from their respective species but may have originated from different tissues other than the heart (e.g. mouse liver, human HeLa cells). Tissue-specific PTM distribution is a matter of intense investigation.

MS technologies used in PTM studies often parallel those of proteome profiling. MS ionization techniques such as electrospray ionization and matrix-assisted laser desorption/ionization ([@bib28]) have been extensively used to study mitochondrial PTMs, with electrospray ionization commonly coupled to upstream LC separation and matrix-assisted laser desorption/ionization coupled with gel-based separation. For tandem MS (MS/MS) experiments, various fragmentation mechanisms have been used; because of the benefit afforded by electron transfer dissociation in preserving peptide backbone information for PTM analyses, it has been applied complementarily with conventional collision-induced dissociation to maximize the revelation of phosphorylation sites ([@bib13]).

Characterization of PTM functions and their regulations in disease additionally requires the degree of modifications to be measured and compared across samples. In this regard, traditional 2D-DIGE ([@bib25]) in conjunction with spot identification by MS has been applied to quantify mitochondrial PTMs; iTRAQ has been performed with high-resolution Orbitrap mass spectrometers through the fragmentation mechanism known as high-energy collision dissociation ([@bib4]).

An emerging MS quantification technology for mitochondrial PTM peptides is targeted multiple reaction monitoring (MRM) using a triple-quadrupole mass spectrometer. An MRM assay can specifically identify peptides through their signature transition ions and LC retention times and is tremendously valuable in demarcating modification sites in proximity. Although present transition prediction algorithms for PTM peptides remain immature and thus the attainment of assay transitions for a specific PTM demands lapidary experimentation and validation, the transitions of PTM sites become a valuable resource for all researchers once deduced. When incorporated with stable isotope internal standards, MRM assays are capable of sensitive and site-specific determination of the absolute quantity of many distinct modification sites in one experiment ([@bib32]).

Finally, the cardinal challenge in the identification and quantification of PTMs pertains to the transiency and low stoichiometry of protein modifications. The use of PTM-specific enrichments before MS acquisition is thus virtually obligatory for any analysis to reduce sample complexity and enhance the sensitivity of detection. Several methods have been exploited to selectively enrich phosphopeptides from the proteome, such as strong cation exchange ([@bib4]), titanium dioxide ([@bib13]; [@bib32]), and immobilized metal ion affinity chromatography ([@bib34]). Immunoprecipitation-based extraction has been harnessed to enrich a wide range of modifications, including acetylated proteins through anti-acetyllysine antibodies ([@bib29]; [@bib8]), whereas biotin-switch assay with avidin affinity column has enabled S-nitrosylated peptides to be distinguished and isolated ([@bib52]). Lastly, O-GlcNAcylated peptides can be enriched by enzymatic chemical tagging ([@bib57]) or antibodies. The ensuing yield, rich in peptides containing the modifications of interest, could be identified and quantified by the aforementioned techniques.

Mitochondrial proteomes in pathogenesis and pathophysiology
===========================================================

As the central hubs of energy production and other important signaling pathways, mitochondria are predisposed to be entangled in numerous human pathological phenotypes. Dysfunction of mitochondrial proteins caused by either environmental changes or genetic mutations has been shown to be directly associated with various diseases including cardiomyopathies, diabetes, and neurodegenerative disorders.

Mitochondrial proteomic analyses in heart failure and cardioprotection.
-----------------------------------------------------------------------

Mitochondria comprise ∼35--40% of the volume of cardiomyocytes ([@bib42]); it is not surprising that many mitochondrial proteomic studies focus on heart tissues to gain insight into the alterations of the mitochondrial proteome under different cardiac phenotypes including heart failure ([@bib21]; [@bib24]). As [@bib24] reported, a commonality among patients with end-stage heart failure revealed a down-regulation of four mitochondrial enzymes involved in the metabolic production of energy including VDAC1, PDH E3-binding protein, ATP synthase D chain, and malate dehydrogenase; these changes were detected by using 2-DE accompanied by protein identification with LC-MS/MS. However, proteins of the ETC were dichotomous with the majority of the proteins appearing in lower abundances and greater abundances present in only 10 ETC proteins in complexes I, II, IV, and V. Intermittent hypoxia (IH) training improves cardioprotection by developing an adjustment to reduced oxygen. After IH training in rats, mitochondrial aconitase, malate dehydrogenase, and the electron transfer flavoprotein α subunit used in lipid metabolism were found to be up-regulated ([@bib49]). In contrast, two proteins, aspartate aminotransferase and the ubiquinol cytochrome c reductase iron sulfur subunit, were down-regulated upon exposure to IH ([@bib49]). Before the introduction of myocardial ischemia, IH treatment promoted more prominent ATP reserves ([@bib36]; [@bib49]). Although myocardial ischemia typically impairs cardiac and metabolic function, a comparison of myocardial ischemic--induced normoxic rats and IH-treated rats resulted in significantly higher ATP levels in IH-treated rats both after 30 min of ischemia as well as after 30 min of reperfusion; the IH-treated rats not only showed a greater tolerance for ischemic insult but also exhibited significantly enhanced ATP reserves both before and after myocardial ischemia/reperfusion ([@bib37]; [@bib40]; [@bib63]). Generation of ROS has been shown to be detrimental to mitochondria; however, peroxiredoxin 5 can inhibit the production of ROS and remove hydrogen peroxide from the system. Previous studies have revealed that IH treatment elevated levels of antioxidant enzymes such as thioredoxin and antioxidant glutathione ([@bib37]). Increased expression of peroxiredoxin 5, a thioredoxin peroxidase, has been reported to be an adjunct to IH training ([@bib21]; [@bib63]). In addition, heat shock protein 60 has been found to alter the ratio of Bcl-2/Bax in favor of preventing ischemia--reperfusion apoptosis, protecting the cell from rupturing ([@bib21]; [@bib63]).

Mounting evidence has shown that alterations of mitochondrial PTMs also contribute to cardioprotection ([@bib7]; [@bib11]; [@bib38]; [@bib46]). PKCε has been reported to translocate to the mitochondria and phosphorylate proteins such as aldehyde dehydrogenase 2 and α-ketoglutarate dehydrogenase. This molecular modification leads to a decrease in ROS production, resulting in cardioprotection ([@bib7]; [@bib31]). Inhibition of glycogen synthase kinase moderates the transportation of ATP, whereas activation of glycogen synthase kinase phosphorylates cyclophillin D, thereby triggering the activation of the mitochondrial permeability transition pore. In addition, nitric oxide indirectly acts as an inhibitory mechanism in the generation of ROS ([@bib52]; [@bib38]); it promotes increases in SNO of complex I, consequently reducing ROS production. Furthermore, SNO causes ATP synthase to reverse its function, prompting a depletion of ATP. SNO has also been ascertained to inhibit irreversible oxidation of proteins. Modifications of mitochondrial proteins and PTMs can lead to alterations in cardiac function. A comprehensive understanding of the mitochondrial proteome will continue to support the advancement of our knowledge in cardiac physiology and cardiac dysfunction.

Mitochondrial proteomic analyses in metabolic disorder--related diseases.
-------------------------------------------------------------------------

The development of diabetes mellitus typically accompanies the dysfunction of insulin production and absorption by the body ([@bib3]). Using 2-DE followed by LC-MS/MS analyses, recent studies from [@bib53] observed the decreased expression of the Ndufs3 protein subunit of complex I in steptozotocin-induced type 1 diabetic rats. In combination with genetic (a decreased mRNA level) as well as biochemical (impaired catalytic activity of complex I) evidence, this group of investigators concluded that Ndufs3 is a critical contributor to the onset of diabetic encephalopathy in type 1 diabetes ([@bib53]). Through the use of iTRAQ and 2D-DIGE, subsarcolemmal mitochondria (SSM) and interfibrillar mitochondria (IFM) were analyzed to determine whether type 1 diabetes influenced the proteomic makeup of these two mitochondrial subpopulations in the heart ([@bib3]). The proteomic makeup of IFM was affected to a greater extent than SSM, as exemplified by a decrease in fatty acid oxidation and OXPHOS proteins. Compared with diabetic SSM, the expression levels of adenine nucleotide translocator, mitochondrial phosphate carrier, mitofilin, inner membrane translocases, and mitochondrial heat shock protein 70 were decreased in diabetic IFM. The levels of mitochondrial protein import were unchanged in diabetic SSM, whereas the levels of mitochondrial protein import were substantially decreased in diabetic IFM ([@bib3]; [@bib12]). PTMs, specifically protein oxidations and deamidations, were more prevalent within IFM. Therefore, proteomic alterations were linked to the dysfunction of mitochondrial protein import such as mitochondrial heat shock protein 70. This evidence underscores the role of the mitochondrial proteomes underlying pathophysiology of diabetes.

Many mitochondrial disease--related phenotypes are associated with excessive ROS, including aging. The body typically counteracts the effects of low amounts of ROS with antioxidant defenses (e.g., MnSOD); as it ages, the antioxidative ability decreases, resulting in enhanced oxidant production. Mitochondrial ETC activity diminishes with aging in humans and other primates; this decline is associated with an increase of mtDNA mutations. An accumulation of mtDNA mutations aggravates the defects in OXPHOS machinery, eventually resulting in energetic failures. Mitochondrial calcium levels also contribute to the aging process as mitochondria become more sensitive to intracellular calcium overload. During aging, the expression and activity of calcium regulating proteins are reduced, leading to a disturbed calcium extrusion ([@bib35]). This intracellular calcium overload directly damages the activation of proteases, nucleases, and calcium-dependent phospholipases, as well as indirectly hindering the OXPHOS machinery, diminishing the supply of ATP and triggering additional ROS release. As part of the aging process, additional roles of mitochondria remain to be elucidated.

Respiratory chain diseases (RCDs) occupy a large subcategory of mitochondrial disorders and are considered among the most common genetic metabolic disorders. Approximately 20% of RCDs are caused by mtDNA mutations, with the remaining RCDs resulting from nuclear anomalies ([@bib14]; [@bib6]; [@bib56]). Defects of proteins within the five complexes of the ETC have been implicated in certain diseases. All proteins encoded by mtDNA (referred to as MT) are linked to diseases such as Leber's hereditary optic neuropathy, including MT-ND1, MT-ND2, MT-ND4, MT-ND4L, MT-ND6, and MT-CYB. In parallel, cardiomyopathies are affiliated with mtDNA mutations in MT-ND2, MT-CYB, and MT-CO1. Additional examples include myoclonic seizures affiliated with mutations in MT-ND3, Leigh's syndrome (LS) (MT-ND5 and MT-CO3), mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes or MELAS (MT-ND5, MT-ND6, MT-CYB, and MT-CO2), Parkisonism (MT-CYB), and myoglobinuria (MT-CO1 and MT-CO3). In addition, six particular nuclear-encoded subunits of complex I (NDUFS1, NDUFS2, NDUFS4, NDUFS7, NDUFS8, and NDUFV1) have been associated with LS and leukodystrophy. Each individual subunit in complex II is involved in the synthesis of diseases including LS, paraganglioma, and pheochromocytoma. The complex III mitochondrial chaperone BCS1 is also linked to GRACILE syndrome, in addition to LS. The occurrence of these insults can arise during disruptions of mutations or deletions in oogenesis, early embryogenesis, or transcription/translation. In addition, the differential expression of the OXPHOS subproteomes within various tissues can entail a tissue-specific phenotype of particular RCDs because of the different metabolic needs of diverse tissue types ([@bib27]; [@bib2]). Complete characterization of the OXPHOS subproteome, its biochemical properties, and its biological functions will further our understanding of RCDs in terms of providing prospective diagnostic biomarkers and therapeutic targets in the detection of RCDs.

Conclusion and future perspectives
==================================

Contextualization of mitochondrial proteins to their biological pathways and their corresponding linkages to clinical phenotypes affords great opportunities to advance our understanding regarding the fundamentals of mitochondrial diseases. Proteomics investigations in the past 15 years have paved a foundation for future studies to establish a comprehensive mitochondrial proteome map. Several challenges remain. At the technology front, these include the identification of proteins in low abundance, proteins that are associated with mitochondria, or proteins with unique biochemical features. Future tasks detailing comprehensive and quantitative characterization of the mitochondrial protein PTMs are also daunting. In the biology arena, functional information regarding individual components within many mitochondrial subproteomes is far from completion. Characterization of these proteins may lead to the discovery of novel mitochondrial functions, of which we are not yet aware. Integrating MS strategies with other approaches such as computational biology, protein arrays, and biochemical analyses will facilitate the advancement and completion of a mitochondrial proteome knowledgebase. The ultimate goal of mitochondrial proteome research is to bridge the knowledge gap between mitochondrial compositions and their functionalities, therefore providing potential diagnostic and prognostic targets for mitochondrial-associated diseases.
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